Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23099062 | 0.82 | NOTUM (0.42) | HTR2AHTR2CSLC6A4MAOBKMT2A | |
| SCHEMBL23087249 | 0.81 | CSF1R (0.36) | HTR2AALDH1A1SMN1; SMN2 | |
| SCHEMBL23087786 | 0.81 | PRMT5 (0.48) | ALKBH1HTR2AHTR2CSLC6A4ALDH1A1 | |
| SCHEMBL23087256 | 0.77 | PRMT5 (0.45) | HTR2AHTR2CALDH1A1MAOBMAPK14 | |
| SCHEMBL23105041 | 0.70 | PRMT5 (0.44) | HTR2AHTR2CALDH1A1HPGD | |
| SCHEMBL23087293 | 0.69 | HTR2A (0.49) | ALKBH1HTR2AHTR2CMAOBSMN1; SMN2 | |
| SCHEMBL9270379 | 0.68 | FFAR1 (0.64) | ALKBH1PLAUALDH1A1KDM4EHPGD | |
| SCHEMBL23087744 | 0.68 | PRMT5 (0.51) | SLC6A4KDM4EHPGDMAOBKMT2A | |
| SCHEMBL515210 | 0.67 | ALDH1A1 (0.48) | PLAUALDH1A1KDM4EFFAR1MAOB | |
| SCHEMBL27164556 | 0.67 | CYP19A1 (0.44) | HTR2AHTR2CSLC6A4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALKBH1 1770/4885HTR2A 4615/4885HTR2C 4713/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | ALKBH1 2900/4885HTR2A 4300/4885HTR2C 3677/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALKBH1 1417/4885HTR2A 4457/4885HTR2C 4536/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALKBH1 1417/4885HTR2A 4457/4885HTR2C 4536/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALKBH1 1770/4885HTR2A 4615/4885HTR2C 4713/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ALKBH1 1417/4885HTR2A 4457/4885HTR2C 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.